Topical propranolol hydrochloride gel for superficial infantile hemangiomas

  • Lie Wang (王 烈)
  • Yin Xia (夏 印)
  • Yanan Zhai (翟亚楠)
  • Chengjin Li (黎成金)
  • Yiqing Li (李毅清)
Article

Summary

The clinical efficacy and safety of topical propranolol hydrochloride gel in the treatment of superficial infantile hemangiomas (IHs) were assessed. Fifty-one cases of IHs from Oct. 2010 to Sept. 2011 were subjected to the topical propranolol hydrochloride gel intervention in Fuzhou General Hospital of Nanjing Military Commands, China. Changes in size, texture, color, peak systolic velocity of the hemangiomas, resistance index and adverse effects were observed. The results were evaluated by using Achauer system, and responses of IHs to pranpronolol were considered scale II (poor) in 4 patients (17.24%), scale II (moderate) in 18 patients (24.14%), scale III (good) in 22 patients (44.83%) and scale IV (excellent) in 7 patients (13.79%). The response of superficial hemangiomas was significantly better than other hemangiomas (P<0.05), and no differences in response were found among different primary sites (P>0.05). Our study indicates that topical application of 3% propranolol hydrochloride gel is effective and safe in treating IHs.

Key words

propranolol hydrochloride gel infantile hemangiomas 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propanolol for severe hemangiomas of infancy. N Engl J Med, 2008,358(24):2649–2651PubMedCrossRefGoogle Scholar
  2. 2.
    Schiestl C, Neuhaus K, Zoller S, et al. Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas. Eur J Pediatr, 2011,170(4):493–501PubMedCrossRefGoogle Scholar
  3. 3.
    Achauer BM, Chang CJ, Vander Kam VM. Management of hemangioma of infancy: review of 245 patients. Plast Reconstr Surg, 1997,99(5):1301–1308PubMedCrossRefGoogle Scholar
  4. 4.
    de Graaf M, Breur JM, Raphaël MF, et al. Adverse effects of propranolol when used in the treatment of hemangiomas: A case series of 28 infants. J Am Acad Dermatol, 2011,65(2):320–327PubMedCrossRefGoogle Scholar
  5. 5.
    Lv YX, Chen SQ, Wang B, et al. Clinical observations of effects of oral propranolol on infantile hemangioma. Zhonghua Xiaoer Waike Zazhi (Chinese), 2011,32(5): 326–329Google Scholar
  6. 6.
    Zvulunov A, McCuaig C, Frieden IJ, et al. Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: a multicenter retrospective study. Pediatr Dermatol. 2011,28(2):94–98PubMedCrossRefGoogle Scholar
  7. 7.
    Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol, 2010,163(2):269–274PubMedCrossRefGoogle Scholar
  8. 8.
    Itinteang T, Brasch HD, Tan ST, et al. Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. J Plast Reconstr Aesthet Surg, 2011,64(6):759–765PubMedCrossRefGoogle Scholar

Copyright information

© Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Lie Wang (王 烈)
    • 1
  • Yin Xia (夏 印)
    • 1
  • Yanan Zhai (翟亚楠)
    • 1
  • Chengjin Li (黎成金)
    • 1
  • Yiqing Li (李毅清)
    • 2
  1. 1.Department of General SurgeryFuzhou General Hospital of Nanjing Military CommandsFuzhouChina
  2. 2.Department of Vascular Surgery, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations